Conference Coverage

Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients


 

REPORTING FROM ACOG 2018


The reason universal surgery was the lowest is because most of these women will be premenopausal at the time of surgery, according to Dr. Kwon. A procedure like a premenopausal oophorectomy has been associated with a 40% increase in all-cause mortality, putting the patient at unnecessary risk, she noted.

Financially, no BRCA testing cost the least, an average of $8,524 Canadian dollars (about US$6,648) followed by universal BRCA at CA$10,103 (about US$7,880) . Universal surgery, with no BRCA testing, cost CA$13,959 (about US$10,888).

Despite the increased cost, the chance to give patients who may be at risk for ovarian cancer a better chance is a good investment, according to Dr. Kwon.

Recommended Reading

Combined PARP, checkpoint inhibitor regimens show ovarian cancer activity
MDedge Hematology and Oncology
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
MDedge Hematology and Oncology
VIDEO: Cervical cancer laparotomy outperforms minimally invasive surgery
MDedge Hematology and Oncology
VIDEO: Interventions target opioid overprescribing after gynecologic surgery
MDedge Hematology and Oncology
Residual single-site ovarian cancer surpasses multisite outcomes
MDedge Hematology and Oncology
Trastuzumab plus chemo shows efficacy for high HER2 endometrial cancer
MDedge Hematology and Oncology
VIDEO: Indocyanine green finds more sentinel lymph nodes
MDedge Hematology and Oncology
Disproportionately low U.S. research funding targets gynecologic cancers
MDedge Hematology and Oncology
What is HIPEC?
MDedge Hematology and Oncology
Leg lymphedema after gynecologic lymphadenectomy exceeds expectations
MDedge Hematology and Oncology